Use of alpha-lipoic acid in prevention of contrast-induced nephropathy in diabetic patients

Renal Failure

Volumn 35, Issue 5, 2013, Pages 748-753

  Cicek, Mutlu ^a   Yildirir, Aylin ^a   Okyay, Kaan ^a   Yazici, Ayse Canan ^a   Aydinalp, Alp ^a   Kanyilmaz, Suleyman ^a   Muderrisoglu, Haldun ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

Alpha lipoic acid; Contrast medium; Diabetes mellitus; Nephropathy; Prevention

Indexed keywords

CREATININE; CYSTATIN C; IOHEXOL; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; THIOCTIC ACID;

ADULT; AGED; ANGIOCARDIOGRAPHY; ANTIOXIDANT ACTIVITY; ARTICLE; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETIC PATIENT; FEMALE; HUMAN; HYDRATION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PILL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REPEAT PROCEDURE; RISK ASSESSMENT;

ADULT; AGED; AGED, 80 AND OVER; ANTIOXIDANTS; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; DIABETES COMPLICATIONS; FEMALE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; THIOCTIC ACID;

EID: 84877866283     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2013.790298     Document Type: Article

References (32)

1. Davidson C, Stacul F, McCullough PA, et al. CIN consensus working panel. Contrast medium use. Am J Cardiol. 2006;98:42K-52K.
2. McCullough PA, Adam A, Becker CR, et al. CIN consensus working panel. Epidemiology and prognostic implications of contrast-induced nephropathy. Am J Cardiol. 2006;98:5K-13K.
3. Briguori C, Airoldi F, Andrea DD, et al. Renal insufficiency following contrast media administration trial (REMEDIAL): A randomized comparison of 3 preventive strategies. Circulation. 2007;115:1211-1217 (Pubitemid 46594764)
4. McCullough P. Outcomes of contrast-induced nephropathy: Experience in patients undergoing cardiovascular intervention. Catheter Cardiovasc Interv. 2006;67:335-343 (Pubitemid 43346729)
5. Cronin RE. Contrast-induced nephropathy: Pathogenesis and prevention. Pediatr Nephrol. 2010;25:191-204
6. Pannu N, Wiebe N, Math M, Stat P, Tonelli M. Prophylaxis strategies for contrast-induced nephropathy. J Am Med Assoc. 2006;295:2765-2779
7. Persson PB, Tepel M. Contrast medium-induced nephropathy: The pathophysiology. Kidney Int. 2006;69:8-10
8. Goldenberg I, Matetzky S. Nephropathy induced by contrast media: Pathogenesis, risk factors and preventive strategies. CMAJ. 2005;172:1461-1471 (Pubitemid 40803495)
9. Lindholt JS. Radiocontrast induced nephropathy. Eur J Vasc Endovasc Surg. 2003;25:296-304 (Pubitemid 36527626)
10. Stacul F, Adam A, Becker CR, et al. CIN consensus working panel. Strategies to reduce the risk of contrast induced nephropathy. Am J Cardiol. 2006;98:59-77
11. Gruberg L, Mintz GS, Mehran R, et al. The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency. J Am Coll Cardiol. 2000;36:1542-1548
12. Rihal CS, Textor SC, Grill DE, et al. Incidence and prognostic importance of renal failure after percutaneous coronary intervention. Circulation. 2002;105:2259-2264 (Pubitemid 34535335)
13. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: Development and initial validation. J Am Coll Cardiol. 2004;44:1393-1399 (Pubitemid 39303939)
14. Sketch MH Jr, Whelton A, Schollmayer E, et al. Prostaglandin E1 Study Group. Prevention of contrast media-induced renal dysfunction with prostaglandin E1: A randomized, double-blind, placebo-controlled study. Am J Ther. 2011;8:155-162
15. Gare M, Haviv YS, Ben-Yehuda A, et al. The renal effect of lowdose dopamine in high-risk patients undergoing coronary angiography. J Am Coll Cardiol. 1999;34:1682-1688
16. Stone GW, McCullough PA, Tumlin JA, et al. CONTRAST investigators. Fenoldopam mesylate for the prevention of contrast-induced nephropathy: A randomized controlled trial. J Am Med Assoc. 2003;290:2284-2291 (Pubitemid 37430561)
17. Matejka J, Varvarovsky I, Vojtisek P, et al. Prevention of contrast-induced acute kidney injury by theophylline in elderly patients with chronic kidney disease. Heart Vessels. 2010;25:536-542
18. Khoury Z, Schlicht JR, Como J, et al. The effect of prophylactic nifedipine on renal function in patients administered contrast media. Pharmacotherapy. 1995;15:59-65
19. Patel K, King CA, Jovin IS. Angiotensin-converting enzyme inhibitors and their effects on contrast-induced nephropathy after cardiac catheterization or percutaneous coronary intervention. Cardiovasc Revasc Med. 2011;12:90-93
20. ACT Investigators. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: Main results from the randomized Acetylcysteine for Contrast-induced nephropathy Trial (ACT). Circulation. 2011;124:1250-1259
21. Cakatay U. Pro-oxidant actions of α-lipoic acid and dihydrolipoic acid. Med Hypotheses. 2006;66:110-117 (Pubitemid 41605115)
22. Sehirli O, Sener E, Cetinel S, Yuksel M, Gedik M, Sener G. Alipoic acid protects against renal ischemia-reperfusion injury in rats. Clin Exp Pharmacol Physiol. 2008;35:249-255 (Pubitemid 351257873)
23. Khabbazi T, Mahdavi R, Safa J, Pour-Abdollahi P. Effects of alpha-lipoic acid supplementation on inflammation, oxidative stress, and serum lipid profile levels in patients with endstage renal disease on hemodialysis. J Ren Nutr. 2012;22:244-250
24. Briguori C, Visconti G, Rivera NV, et al. Cystatin C and contrast-induced acute kidney injury. Circulation. 2010;121:2117-2122
25. Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A. NGAL Meta-Analysis Investigator Group. Accuracy of neutrophil gelatinase-Associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: A systematic review and meta-Analysis. Am J Kidney Dis. 2009;54:1012-1024
26. Malyszko J, Bachorzewska-Gajewska H, Poniatowski B, et al. Urinary and serum biomarkers after cardiac catheterization in diabetic patients with stable angina and without severe chronic kidney disease. Ren Fail. 2009;31:910-919
27. Singh U, Jialal I. Alpha lipoic acid supplementation and diabetes. Nutr Rev. 2008;66:646-657
28. McIlduff CE, Rutkove SB. Critical appraisal of the use of alpha lipoic acid (thioctic acid) in the treatment of symptomatic diabetic polyneuropathy. Ther Clin Risk Manag. 2011;7:377-385
29. Koga H, Hagiwara S, Kusaka J, et al. New α-lipoic acid derivative, DHL-HisZn, ameliorates renal ischemia-reperfusion injury in rats. J Surg Res. 2012;174:352-358
30. Jo SH, Kim HS, Lee JH, et al. Evaluation of alpha lipoic acid to prevent contrast induced nepphropathy: A prospective randomised trial. In: Angioplasty Summit Abstracts, E-Poster, Fourteenth Annual Symposium: Angioplasty Summit 2009 TCT Asia Pacific, April 22-29, 2009
31. Ling W, Zhaohui N, Ben H, et al. Urinary IL-18 and NGAL as early predictive biomarkers in contrast-induced nephropathy after coronary angiography. Nephron Clin Pract. 2008;108: C176-c181 (Pubitemid 351588109)
32. Li W, Li D, Xu T, Zhang Y, Zhu H, Han F. The value of urinary NGALon the early diagnosis of contrast induced nephropathy in patients undergoing percutaneous coronary intervention. Heart. 2011;97:A150